VAXCYTE, INC. Earnings Per Share (Diluted)
VAXCYTE, INC. (PCVX) reported Earnings Per Share (Diluted) of -$1.97 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-05
- VAXCYTE, INC. earnings per share, diluted for the quarter ending 2026-06-30 was -$1.97.
- VAXCYTE, INC. earnings per share, diluted for the quarter ending 2026-03-31 was -$2.30.
- VAXCYTE, INC. earnings per share, diluted for the quarter ending 2025-12-31 was $3.81, a 57.69% increase year-over-year.
- VAXCYTE, INC. earnings per share, diluted for the quarter ending 2025-09-30 was -$1.56.
- VAXCYTE, INC. earnings per share, diluted for fiscal 2025 was -$5.63.
- VAXCYTE, INC. earnings per share, diluted for fiscal 2024 was -$3.80.
- VAXCYTE, INC. earnings per share, diluted for fiscal 2023 was -$4.14.
- VAXCYTE, INC. earnings per share, diluted for fiscal 2022 was -$3.44.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.97 10-Q · filed 2026-08-05 | -$4.26 10-Q · filed 2026-08-05 | -$0.61 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$2.14 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2026-03-31 | -$2.30 10-Q · filed 2026-05-06 | $1.44 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.10 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1.32 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-12-31 | $3.81 derived: net income ÷ weighted average shares · filed 2026-04-23 | $2.25 derived: net income ÷ weighted average shares · filed 2026-04-23 | $1.03 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$5.63 10-K · filed 2026-02-24 |
| 2025-09-30 | -$1.56 10-Q · filed 2025-11-04 | -$2.79 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$3.83 10-Q · filed 2025-11-04 | -$1.43 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-06-30 | -$1.22 10-Q · filed 2026-08-05 | -$2.26 10-Q · filed 2026-08-05 | $0.14 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.63 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-03-31 | -$1.04 10-Q · filed 2026-05-06 | $1.37 derived: net income ÷ weighted average shares · filed 2026-08-05 | $0.63 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.36 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2024-12-31 | $2.41 derived: net income ÷ weighted average shares · filed 2026-04-23 | $1.72 derived: net income ÷ weighted average shares · filed 2026-04-23 | $0.75 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$3.80 10-K · filed 2026-02-24 |
| 2024-09-30 | -$0.83 10-Q · filed 2025-11-04 | -$1.92 derived: net income ÷ weighted average shares · filed 2025-11-04 | -$2.78 10-Q · filed 2025-11-04 | -$0.93 derived: net income ÷ weighted average shares · filed 2026-04-23 |
| 2024-06-30 | -$1.10 10-Q · filed 2025-08-06 | -$1.95 10-Q · filed 2025-08-06 | -$0.02 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$0.88 derived: net income ÷ weighted average shares · filed 2026-04-23 |
| 2024-03-31 | -$0.85 10-Q · filed 2025-05-07 | $1.18 derived: net income ÷ weighted average shares · filed 2026-04-23 | $0.32 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-04-23 |
| 2023-12-31 | $2.16 derived: net income ÷ weighted average shares · filed 2026-04-23 | $1.26 derived: net income ÷ weighted average shares · filed 2026-04-23 | $0.60 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$4.14 10-K · filed 2026-02-24 |
| 2023-09-30 | -$0.91 10-Q · filed 2024-11-05 | -$1.61 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$2.32 10-Q · filed 2024-11-05 | -$0.84 derived: net income ÷ weighted average shares · filed 2026-04-23 |
| 2023-06-30 | -$0.70 10-Q · filed 2024-08-06 | -$1.40 10-Q · filed 2024-08-06 | $0.19 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$0.51 derived: net income ÷ weighted average shares · filed 2026-04-23 |
| 2023-03-31 | -$0.70 10-Q · filed 2024-05-08 | $1.03 derived: net income ÷ weighted average shares · filed 2026-04-23 | $0.35 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$0.30 derived: net income ÷ weighted average shares · filed 2026-04-23 |
| 2022-12-31 | $1.84 derived: net income ÷ weighted average shares · filed 2026-04-23 | $1.24 derived: net income ÷ weighted average shares · filed 2026-04-23 | $0.58 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$3.44 10-K · filed 2025-02-25 |
| 2022-09-30 | -$0.93 10-Q · filed 2023-11-06 | -$1.73 derived: net income ÷ weighted average shares · filed 2023-11-06 | -$2.42 10-Q · filed 2023-11-06 | -$1.27 derived: net income ÷ weighted average shares · filed 2026-04-23 |
| 2022-06-30 | -$0.80 10-Q · filed 2023-08-08 | -$1.48 10-Q · filed 2023-08-08 | -$0.28 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$0.77 derived: net income ÷ weighted average shares · filed 2026-04-23 |
| 2022-03-31 | -$0.68 10-Q · filed 2023-05-08 | $0.59 derived: net income ÷ weighted average shares · filed 2026-04-23 | $0.11 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$0.33 derived: net income ÷ weighted average shares · filed 2026-04-23 |
| 2021-12-31 | $1.35 derived: net income ÷ weighted average shares · filed 2026-04-23 | $0.85 derived: net income ÷ weighted average shares · filed 2026-04-23 | $0.40 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$1.93 10-K · filed 2024-02-27 |
| 2021-09-30 | -$0.51 10-Q · filed 2022-11-07 | -$0.97 derived: net income ÷ weighted average shares · filed 2022-11-07 | -$1.39 10-Q · filed 2022-11-07 | |
| 2021-06-30 | -$0.46 10-Q · filed 2022-08-08 | -$0.87 10-Q · filed 2022-08-08 | ||
| 2020-12-31 | -$3.02 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |